{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:46:31Z","timestamp":1790257591947,"version":"4.1.0"},"reference-count":25,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,6,24]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare haematological malignancy defined by concurrent expression of CD4, CD56, BCL-2 and CD123. The disease has a very poor prognosis and there are no well-established treatment guidelines. We describe a case of BPDCN in a 65-year-old female patient with myeloproliferative disorder (essential thrombocythemia) and chronic lymphocytic leukaemia. She presented with rapidly progressive facial and scalp lesions. Skin biopsy confirmed BPDCN and the imaging revealed widespread disease. Patient was started on hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) and intrathecal methotrexate. Due to progression on initial treatment, she was treated with decitabine and venetoclax (BCL-2 inhibitor). However, patient continued to deteriorate and died after 4\u2009months from initial diagnosis. We emphasise on the clinical features, emerging treatment modalities and prognosis of BPDCN.<\/jats:p>","DOI":"10.1136\/bcr-2019-230332","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T08:25:28Z","timestamp":1563179128000},"page":"e230332","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-0766","authenticated-orcid":false,"given":"Abdul Moiz","family":"Khan","sequence":"first","affiliation":[{"name":"Internal Medicine, Albany Medical Center Hospital, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Munir","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albany Medical Center Hospital, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Raval","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Albany Medical Center Hospital, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mehdi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Albany Stratton VA Medical Center, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"2025082800513991000_12.7.e230332.1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol"},{"key":"2025082800513991000_12.7.e230332.2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/modpathol.2015.145","article-title":"Neoplasms derived from plasmacytoid dendritic cells","volume":"29","author":"Facchetti","year":"2016","journal-title":"Mod Pathol"},{"key":"2025082800513991000_12.7.e230332.3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"key":"2025082800513991000_12.7.e230332.4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/107327481402100404","article-title":"Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy","volume":"21","author":"Riaz","year":"2014","journal-title":"Cancer Control"},{"key":"2025082800513991000_12.7.e230332.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1556"},{"key":"2025082800513991000_12.7.e230332.6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11899-018-0489-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm","volume":"13","author":"Khoury","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2025082800513991000_12.7.e230332.7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-018-3259-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents","volume":"97","author":"Wang","year":"2018","journal-title":"Ann Hematol"},{"key":"2025082800513991000_12.7.e230332.8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072645"},{"key":"2025082800513991000_12.7.e230332.9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2023"},{"key":"2025082800513991000_12.7.e230332.10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12412"},{"key":"2025082800513991000_12.7.e230332.11","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0101-RS"},{"key":"2025082800513991000_12.7.e230332.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08556.x"},{"key":"2025082800513991000_12.7.e230332.13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.47"},{"key":"2025082800513991000_12.7.e230332.14","first-page":"322","article-title":"Composite dendritic cell neoplasm (NOS) and small lymphocytic lymphoma","volume":"8","author":"Harvell","year":"2000","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2025082800513991000_12.7.e230332.15","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.16"},{"key":"2025082800513991000_12.7.e230332.16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3390\/cancers11050595","article-title":"Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects","volume":"11","author":"Sapienza","year":"2019","journal-title":"Cancers"},{"key":"2025082800513991000_12.7.e230332.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0999"},{"key":"2025082800513991000_12.7.e230332.18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169326"},{"key":"2025082800513991000_12.7.e230332.19","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-4"},{"key":"2025082800513991000_12.7.e230332.20","doi-asserted-by":"crossref","unstructured":"Pemmaraju N , Lane AA , Sweet KL , et al . 765 Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). 2018 https:\/\/ash.confex.com\/ash\/2018\/webprogram\/Paper118966.html","DOI":"10.1182\/blood-2018-99-118966"},{"key":"2025082800513991000_12.7.e230332.21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704215"},{"key":"2025082800513991000_12.7.e230332.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621268"},{"key":"2025082800513991000_12.7.e230332.23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ejh.12294","article-title":"Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine","volume":"93","author":"Laribi","year":"2014","journal-title":"Eur J Haematol"},{"key":"2025082800513991000_12.7.e230332.24","first-page":"1356","article-title":"Results of off-label venetoclax use in combination with low-intensity chemotherapy in patients with relapsed and refractory myeloid malignancies","volume":"130","author":"Rausch","year":"2017","journal-title":"Blood"},{"key":"2025082800513991000_12.7.e230332.25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/13543784.2017.1386173","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Gentile","year":"2017","journal-title":"Expert Opin Investig Drugs"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-230332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:51:48Z","timestamp":1756367508000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-230332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,15]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bcr-2019-230332"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-230332","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}